DSGN MEXC RealStocks
Own real DSGN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 23:08:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Design Therapeutics, Inc. (DSGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.47, with a market capitalization of $677.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.81 to $17.25. This page covers its latest market performance, valuation, price trends and company information.
$677.50M | |
$10.60 | |
$10.61 | |
$10.21 | |
$10.58 | |
132.20K | |
579.13K | |
-- | |
$17.25 | |
$6.81 | |
-- | |
-- |
Design Therapeutics, Inc. (DSGN) is trading at $10.47 in after-hours trading as of 2026-11-13 20:59:55, unchanged from the regular-session close of $10.47.
After-hours trading shows how investors are pricing DSGN after the regular session closes. The current after-hours price is near the regular-session close, indicating neutral after-hours sentiment.
Over the past seven days, Design Therapeutics, Inc. (DSGN) moved from $9.67 to $10.47, representing a gain of 8.27% ($0.80).
The stock traded between $9.62 and $11.00 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 382.61 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35.1%
DSGN is currently trading at $10.47, placing it 35.1% of the way from its 52-week low of $6.81 to its 52-week high of $17.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 60 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Design Therapeutics, Inc. (DSGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DSGN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DSGN shares and USD.
DSGN Shares to USD
1.00 DSGN shares = 10.47 USD
Calculations are estimates based on the latest available price and are for reference only.